Prevention Of Delayed Graft Function (“DGF”) In Kidney Transplant Recipients
Entering P2b in the UK under CTA approval already granted, this is our most advanced and lead program, comprised of inhaled CO delivered via our proprietary gas-device-software-dosing product for the prevention of delayed graft function (“DGF”) in kidney transplant recipients. Due to the high and increasing demand for kidneys due to increasing chronic kidney disease – itself due to increasing rates of diabetes and hypertension - clinicians and patients have been increasingly utilizing poorer and poorer quality donor organs which are more prone to ischemia-reperfusion injury (“IRI”). This has resulted in climbing DGF rates, which now are now well in excess of 30% at many centers. CO has been shown in several preclinical studies to be strongly cytoprotective in the setting of IRI, and thus has significant potential to reduce the frequency, severity and duration of DGF. This in turn has the potential to enhance post-transplant outcomes both acutely and chronically and reduce health care costs.
